ライフサイエンスコーパス: oral corticosteroid

1 rnase alfa, inhaled antibiotics, inhaled and oral corticosteroids).

2 t patients by treatment with peri-infusional oral corticosteroid.

3 Twelve patients (92.3%) received oral corticosteroid.

4 with nasal polyps (CRSwNP) are resistant to oral corticosteroids.

5 linical practice trigger the prescription of oral corticosteroids.

6 exacerbations were managed successfully with oral corticosteroids.

7 all prescriptions for asthma medication and oral corticosteroids.

8 versies in therapy, particularly the role of oral corticosteroids.

9 cy department services and/or treatment with oral corticosteroids.

10 l anticholinesterase therapy with or without oral corticosteroids.

11 old higher than in patients not treated with oral corticosteroids.

12 was time to first exacerbation that required oral corticosteroids.

13 ously received this treatment) and high-dose oral corticosteroids.

14 thmatics, even those on high-dose inhaled or oral corticosteroids.

15 of NO inflammation, the latter responsive to oral corticosteroids.

16 mily history of hip fracture, and the use of oral corticosteroids.

17 sideration for prolonged reducing courses of oral corticosteroids.

18 infusions of cyclophosphamide, and high-dose oral corticosteroids.

19 The mainstay of therapy remains oral corticosteroids.

20 subjects, none of whom was taking inhaled or oral corticosteroids.

21 patients) required home oxygen treatment or oral corticosteroids.

22 All participants received topical and oral corticosteroids.

23 and 2 patients received additional systemic oral corticosteroids.

24 ng beta-agonists with or without maintenance oral corticosteroids.

25 prescribed inhaled corticosteroids and 15.6% oral corticosteroids.

26 cy unit)/ICU and to be receiving maintenance oral corticosteroids.

27 d CCL-13 (MCP-4) in both asthma groups after oral corticosteroids.

28 fety advantages over starting treatment with oral corticosteroids.

29 defined mandatory taper to discontinue their oral corticosteroids.

30 bers of severe exacerbations and the dose of oral corticosteroids.

31 sthma who differed in molecular responses to oral corticosteroids.

32 4.1% anti-IgE, 10.7% theophylline, and 16.0% oral corticosteroids.

33 Twenty-two patients had NPs resistant to oral corticosteroids.

34 sation of offending drug and short course of oral corticosteroids.

35 losporine, tacrolimus; 13% [67 of 513]), and oral corticosteroids (11% [54 of 513]).

36 -14.34], theophylline: 2.46 [1.23-4.91], and oral corticosteroids: [2.99;.1.26-7.08]).

37 mong 2073 non-diabetic patients treated with oral corticosteroids, 25 (1.21%) initiated hypoglycemic

38 ial treatment responded, compared to 39% for oral corticosteroids, 36% for vigabatrin, and 9% for oth

39 g the 1891 eligible patients, treatment with oral corticosteroids, 5-aminosalicylates, and other non-

40 b initiation, 65.8% of patients had received oral corticosteroids (74.4%, 60.9% and 66.7% for biologi

41 t included antitubercular therapy (ATT) with oral corticosteroids (93 patients) or corticosteroids al

42 ng life (TTO <=0.8) than patients not taking oral corticosteroids (95% confidence interval: 2.3, 48.1

43 ol was used in eight studies as a measure of oral corticosteroid adherence, and fractional exhaled ni

44 was significantly reduced by treatment with oral corticosteroids (adjusted hazard ratio = 0.32, conf

45 was significantly reduced by treatment with oral corticosteroids (adjusted hazard ratio = 0.32, conf

46 hich was averted in subsequent patients with oral corticosteroids administered during the infusion an

47 Intravenous corticosteroid administration, oral corticosteroid administration, aqueous GWC, and T.

48 des of acute asthma requiring treatment with oral corticosteroids, admission, or a visit to an emerge

49 ynechiae (aHR, 5.9, P = .02), and the use of oral corticosteroid (aHR 28.9; P = .003) at the presenti

50 d and defined as short-course treatment with oral corticosteroids alone or in combination with an ant

51 ng asthma medications (particularly those on oral corticosteroids alone or in combination) were at en

52 Compared with oral corticosteroids alone, are oral antiviral drugs ass

53 Compared with oral corticosteroids alone, the addition of acyclovir, v

54 Oral corticosteroids also had an effect that reduces the

55 The median daily dose of oral corticosteroids among the 165 patients receiving or

56 oint scale) after a 1-hour treatment with an oral corticosteroid and 3 inhaled albuterol and ipratrop

57 Oral corticosteroid and antifungal therapies appear to b

58 s flares, as well as the risk ratios (RR) of oral corticosteroid and nonbiological IMT use, before an

59 index, and have more exacerbations requiring oral corticosteroid and unscheduled primary care attenda

60 ow-release oral theophylline are added, with oral corticosteroids and anti-immunoglobulin E treatment

61 The patient refused oral corticosteroids and any intravitreal injection ther

62 ment with high dose inhaled corticosteroids, oral corticosteroids and azathioprine.

63 )-agonists (LABAs) are frequently exposed to oral corticosteroids and high-dose ICS, which can lead t

64 It demonstrated that, when used properly, oral corticosteroids and immunosuppression can be given

65 Thus, oral corticosteroids and immunosuppression may be a pref

66 veness trial comparing systemic therapy with oral corticosteroids and immunosuppression with regional

67 e, posterior, and panuveitides, treated with oral corticosteroids and immunosuppression, there is a s

68 is, or panuveitis typically are treated with oral corticosteroids and immunosuppressive agents, such

69 h-dose inhaled corticosteroids combined with oral corticosteroids and long-acting beta2-agonists) wer

70 rom the age of fourteen, and the addition of oral corticosteroids and omalizumab to regular inhaled c

71 al follow-up and were primarily managed with oral corticosteroids and other immunosuppressive agents.

72 Dispensation of oral corticosteroids and rate of asthma exacerbations we

73 ng search terms for asthma with keywords for oral corticosteroids and systemic corticosteroids.

74 bgroup analysis of patients not on long-term oral corticosteroids and with baseline FEV1 reversibilit

75 pite treatment with high doses of inhaled or oral corticosteroids and, in cluster D, reduced lung fun

76 (biologic therapy or 3 consecutive months of oral corticosteroids), and revision surgery involving po

77 ents who initiated with mesalazine, 141 with oral corticosteroids, and 143 with intravenous corticost

78 mesalazine, 50.4 (13.8) in those initiating oral corticosteroids, and 66.9 (13.7) in those initiatin

79 suppression comprising cell-cycle inhibitor, oral corticosteroids, and calcineurin inhibitor.

80 patients with asthma, including response to oral corticosteroids, and correlate these sites with exp

81 ing antibiotics, antihistamines, topical and oral corticosteroids, and epinephrine, have been used fo

82 ments of adrenocorticotropic hormone (ACTH), oral corticosteroids, and vigabatrin were considered ind

83 chicine; use of colchicine, allopurinol, and oral corticosteroids; and emergency department (ED) and

84 d at least 2 COPD exacerbations treated with oral corticosteroids, antibiotics, or both in the prior

85 COPD exacerbations requiring treatment with oral corticosteroids, antibiotics, or both.

86 Among patients with RA, DMARDs and/or use of oral corticosteroids appeared to be associated with herp

87 Although oral corticosteroids are commonly prescribed following e

88 Oral corticosteroids are effective in controlling sinona

89 he adverse effects from the long-term use of oral corticosteroids are known, but, to our knowledge, f

90 Oral corticosteroids are the first line of therapy for t

91 Adverse effects of oral corticosteroids are well documented, but less is kn

92 Oral corticosteroids as monotherapy are not associated w

93 and severe asthma exacerbations (ie, use of oral corticosteroids, asthma-related emergency departmen

94 These studies also suggest that oral corticosteroids at doses low enough for safe long-t

95 ); beta-blockers (beta = -1.02; P = .10) and oral corticosteroids (beta = 2.13; P = .07) were margina

96 Oral corticosteroid bursts (defined as oral corticostero

97 thma exacerbations were measured by rates of oral corticosteroid bursts and asthma-related emergency

98 Oral corticosteroid bursts are frequently prescribed in

99 s inversely associated with acute visits and oral corticosteroid bursts, whereas among those in homes

100 fference was observed in visual outcome with oral corticosteroids, but subjects treated with anti-VEG

101 Oral corticosteroids combined with antibiotics may be as

102 sion was 35% among patients who had received oral corticosteroids compared with 42% among those who h

103 es to reduce exacerbations and dependency on oral corticosteroids compared with placebo.

104 Efficacy and safety of azathioprine, oral corticosteroids, cyclosporine, methotrexate, mycoph

105 1)% predicted, asthma control, and long-term oral corticosteroid daily dose-in patients with or witho

106 The lung function response to oral corticosteroids decreased with increasing sputum en

107 roved for moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma, and omalizumab is

108 The average daily dose of inhaled or oral corticosteroids did not differ between the two grou

109 [CI], 0.53-0.77; P < 0.0001) and two or more oral corticosteroid dispensings (OR, 0.90; 95% CI, 0.81-

110 ma exacerbations were defined as two or more oral corticosteroid dispensings, asthma-related emergenc

111 thma-related emergency department visits and oral corticosteroid dispensings.

112 this randomized clinical trial suggest that oral corticosteroids do not enhance vocal cord remobiliz

113 g-acting beta(2)-agonist but not maintenance oral corticosteroid does not preclude a robust clinical

114 c complications increase with the cumulative oral corticosteroid dosage.

115 placebo, allowed a significant reduction in oral corticosteroid dosages in patients with severe asth

116 up exhibited greater cumulative reduction in oral corticosteroid dose (P(inter-intra), -1.05 g [-1.76

117 es suggested that reaching a high cumulative oral corticosteroid dose within a shorter time, with few

118 artment or hospital admissions), maintenance oral corticosteroid dose, and improved Asthma Control Qu

119 pendent corticosteroid dose, age, sex, prior oral corticosteroid dose, prior topical corticosteroid u

120 y disease who are prescribed high cumulative oral corticosteroid doses may decrease fracture-associat

121 Eligible patients who used oral corticosteroids during follow-up were identified an

122 n was defined as zero exacerbations and zero oral corticosteroids during the previous 6 months assess

123 resses the controversial issue of the use of oral corticosteroids during wheezing exacerbations in pr

124 ations (symptoms requiring a short course of oral corticosteroids) during the study was similar in th

125 escalation or >=2 courses of blinded rescue oral corticosteroids) during the study; in addition, pat

126 Nevertheless, the risk of AEs with oral corticosteroids, especially among patients with ato

127 eans 1.22 [1.06-1.41]; p=0.006), but reduced oral corticosteroid exposure (77.5 mg prednisone [240.5]

128 Seventy-three patients with CRSwNP took oral corticosteroids for 15 days.

129 Eighty-one patients with CRSwNP took oral corticosteroids for 15 days.

130 s (29%): methotrexate for 24 patients (23%), oral corticosteroids for 8 patients (8%), and azathiopri

131 haled corticosteroids may be as effective as oral corticosteroids for acute asthma exacerbations.

132 To assess the effects of oral corticosteroids for acute lower respiratory tract i

133 To assess the clinical effectiveness of oral corticosteroids for acute sore throat in the absenc

134 In patients taking long-term oral corticosteroids for chronic lung disease, the relat

135 unity population (more than 50 years) taking oral corticosteroids for chronic lung disease.

136 Moderate to severe UC may require oral corticosteroids for induction of remission as a bri

137 ic mucus hypersecretion, and frequent use of oral corticosteroids for maintenance of asthma control (

138 ere was no increased risk of AEs with use of oral corticosteroids for more than 30 days (adjusted odd

139 ) and 10 561 controls (3.2%) were exposed to oral corticosteroids for more than 30 days, while 684 ca

140 orineural hearing loss has been treated with oral corticosteroids for more than 30 years.

141 In particular, patients who had been taking oral corticosteroids for more than 6 months, regardless

142 eas the risk was slightly higher with use of oral corticosteroids for more than 90 days (AOR, 1.11; 9

143 4%) and 1153 controls (0.4%) were exposed to oral corticosteroids for more than 90 days.

144 f acyclovir, valacyclovir, or famcyclovir to oral corticosteroids for treatment of Bell palsy was ass

145 patients were exacerbation-free, 83.1% were oral corticosteroid-free, 78.1% had partly/well-controll

146 nts in the mesalazine group, 47 (33%) in the oral corticosteroid group, and 30 (21%) in the intraveno

147 nts in the mesalazine group, 21 (15%) in the oral corticosteroid group, and 52 (36%) in the intraveno

148 ed as any of the following: prescription for oral corticosteroids, >5 prescriptions for short acting

149 ct profile similar to, although milder than, oral corticosteroids has emerged.

150 Long-term use of oral corticosteroids has known adverse effects, but the

151 Several new alternatives to oral corticosteroids have been evaluated in severe asthm

152 din analogues, calcium channel blockers, and oral corticosteroids have the largest relative effects.

153 ion with systemic chemotherapy therapies and oral corticosteroids; however, recurrences were common.

154 eeded to help reduce the need for continuous oral corticosteroids; however, there are currently very

155 y in reducing asthma attacks and exposure to oral corticosteroids, important causes of morbidity in p

156 Common therapeutic management included oral corticosteroids in 123 patients (93.2%), intravenou

157 rette smoking on the therapeutic response to oral corticosteroids in chronic stable asthma.

158 ed with improved outcomes when combined with oral corticosteroids in patients presenting within 72 ho

159 ecommendation against the use of maintenance oral corticosteroids in patients with COPD and a history

160 -agonists in asthma, the lack of efficacy of oral corticosteroids in preschool children with acute wh

161 tokine concentrations and their responses to oral corticosteroids in stable chronic asthma is unclear

162 The role of oral corticosteroids in treating patients with exacerbat

163 icosteroids among the 165 patients receiving oral corticosteroids, in prednisone equivalents, was 10

164 ultifocal Hemorrhagic Retinal Vasculitis are oral corticosteroids, intravitreal ganciclovir and laser

165 The use of oral corticosteroids is associated with an increased ris

166 e of nonsteroidal antiinflammatory drugs and oral corticosteroids (</=10 mg/day prednisone or its equ

167 Secondary endpoints included long-term-oral corticosteroid (LTOCS) use, asthma-related emergenc

168 toffs were: 0 exacerbations/yr, no long-term oral corticosteroid (LTOCS), partly/well-controlled asth

169 Treatment with oral corticosteroids may help to reduce the risk of CNVM

170 d point, defined as the need for a course of oral corticosteroids (n = 311) or a reduction in morning

171 428 children initiated mesalazine (n=136), oral corticosteroids (n=144), or intravenous corticoster

172 ents had nasal polyps that were resistant to oral corticosteroids (NP-CR).

173 ions (MENSA) and the percentage reduction in oral corticosteroid (OCS) dose (SIRIUS).

174 Oral corticosteroid (OCS) treatment for severe asthma is

175 Patterns and determinants of long-term oral corticosteroid (OCS) use in asthma and related morb

176 Rationale: There is a need to minimize oral corticosteroid (OCS) use in patients with asthma to

177 o reflect exacerbations: hospital visits and oral corticosteroid (OCS) use in the previous year.

178 herence to inhaled corticosteroids (ICS) and oral corticosteroids (OCS) after discharge in adults hos

179 re for these conditions often still includes oral corticosteroids (OCS) and/or cytotoxic immune thera

180 Over the past 70 years, oral corticosteroids (OCS) have played an important role

181 tions and hospitalizations, reduced need for oral corticosteroids (OCS), improved lung function, decr

182 es such as inhaled corticosteroids (ICS) and oral corticosteroids (OCS).

183 rbations, as well as eosinophil responses to oral corticosteroids (OCS).

184 >= 25 parts per billion without maintenance oral corticosteroid [OCS]; OCS maintenance population: 3

185 dation cohort (relatively high percentage on oral corticosteroids [OCS]).

186 Oral corticosteroids (OCSs) are recommended for severe w

187 Total doses of inhaled corticosteroids and oral corticosteroids (OCSs) were recorded, serum 25-hydr

188 been associated with continuous exposure to oral corticosteroids (OCSs).

189 oid therapy is safer than frequent bursts of oral corticosteroids on bone mineral accretion in this r

190 The effect of oral corticosteroids on FEV1 , Pc20, airway inflammation

191 ens clinically prescribed (antibiotics only, oral corticosteroids only, or both).

192 ealed associations with FVC % predicted, and oral corticosteroid or antileukotriene use.

193 ndomized to receive either a 7-day course of oral corticosteroids or a placebo.

194 e subset of 2,841 exacerbations treated with oral corticosteroids or antibiotics, with recovery 1.29

195 ations were defined as asthma-related use of oral corticosteroids or hospitalizations/emergency depar

196 litis who received concurrent treatment with oral corticosteroids or immunosuppressants.

197 nge, 11 to 50 years) who required inhaled or oral corticosteroids (or both) to receive either placebo

198 efined as no hospital attendance for asthma, oral corticosteroids, or antibiotics for lower respirato

199 prior 3 months requiring hospital attention, oral corticosteroids, or both.

200 tal attendance or admission, acute course of oral corticosteroids, or prescription for antibiotics.

201 he use of rescue therapy or long-term use of oral corticosteroids, or the dispensing of three or more

202 iene modifiers, short-acting beta2-agonists, oral corticosteroids, other bronchodilators, and no medi

203 17) percentages and ratios of patients using oral corticosteroids (P = .035).

204 djusting for the annual number of courses of oral corticosteroids (p trend = 0.007).

205 ls and an impaired lung function response to oral corticosteroids, particularly in asthmatic never sm

206 of more than 30 days or more than 90 days of oral corticosteroid prescription per year.

207 re exacerbations (-21% beyond -36%), and new oral corticosteroid prescriptions (-33% beyond -41%).

208 People with high- and low-intensity oral corticosteroid prescriptions had similar rates of m

209 9.5%] male), individuals with high-intensity oral corticosteroid prescriptions had substantially high

210 sion models comparing high- vs low-intensity oral corticosteroid prescriptions.

211 ised treatment with mesalazine (PUCAI 10-30) oral corticosteroids (PUCAI 35-60), or intravenous corti

212 drug levels in the blood, adherence rates to oral corticosteroids ranged from 47% to 92%, although th

213 termine the association between preadmission oral corticosteroid receipt and the development of acute

214 sion definition consisting of exacerbations, oral corticosteroid receipt, symptom control, and lung f

215 rove lung function, increase withdrawal from oral corticosteroids, reduce frequency of rescue medicat

216 Some also allow oral corticosteroid reduction or elimination in patients

217 5 of 2666 patients (0.19%) not treated with oral corticosteroids (relative risk [RR], 4.39; 95% conf

218 Oral corticosteroids remain the main treatment for these

219 ith increased asthma exacerbations requiring oral corticosteroids (repeated measures logistic regress

220 controlled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic

221 Oral corticosteroids should not be used for acute lower

222 safety events or the treatment effect in the oral corticosteroid subgroup.

223 th short, intermittent courses of inhaled or oral corticosteroids taken when symptoms worsen.

224 extractable results), of patients receiving oral corticosteroids, that compared vitamin D with eithe

225 er adjusting the model for annual courses of oral corticosteroids, the only confounder of note (OR 1.

226 nts with severe asthma who require long-term oral corticosteroid therapy are at risk of unwanted effe

227 ED visits, and 44% reduction in the need for oral corticosteroid therapy at 48 months, the model simu

228 inuation, defined as inactive uveitis and no oral corticosteroid therapy for 2 consecutive study visi

229 ional regional corticosteroid injections and oral corticosteroid therapy for induction of remission.

230 te hospitalizations, ED visits, and need for oral corticosteroid therapy in childhood asthma for plan

231 ind, placebo-controlled trial the effects of oral corticosteroid therapy in patients with exacerbatio

232 al therapy (topical, regionally injected, or oral corticosteroid therapy).

233 nce, 7 (3.2%) continued to receive long-term oral corticosteroid therapy, 5 (2.3%) received biologic

234 lic phenotype, as treatment, including daily oral corticosteroid therapy, suppresses eosinophilic inf

235 rate to severe UC should undergo a course of oral corticosteroid therapy, with transition to 5-ASA, t

236 s, 41% in ED visits, and 46% in the need for oral corticosteroid therapy.

237 vere asthma in spite of high-dose inhaled or oral corticosteroid therapy.

238 ncy department (ED) visits, and the need for oral corticosteroid therapy.

239 prescriptions crossing the 450-mg cumulative oral corticosteroid threshold in less than 90 days were

240 up from the date they crossed the cumulative oral corticosteroid threshold until their outcome or the

241 ammation (inactive disease) and reduction of oral corticosteroids to a prednisone dosage of <=7.5 mg/

242 the current practice of prescribing low-dose oral corticosteroids to all patients with non-acidotic e

243 significant subset of patients that require oral corticosteroids to control symptoms.

244 months of completing ATT, inability to taper oral corticosteroids to less than 10 mg/d or topical cor

245 additional controller with or without daily oral corticosteroids) to patients aged 12 years or older

246 s were discontinued successfully in 76.5% of oral corticosteroid-treated patients (rate = 0.28/PY; 95

247 sparing success was achieved in 95.4% of the oral corticosteroid-treated patients at a rate of 0.60 s

248 orally) or placebo, stratified by the use of oral corticosteroid treatment and bronchoscopy.

249 nchanged in those with asthma who adhered to oral corticosteroid treatment as documented by urinary p

250 e smoking impairs the efficacy of short-term oral corticosteroid treatment in chronic asthma.

251 e prior to the index, the median duration of oral corticosteroid treatment increased from 34 to 88 da

252 0005; hazard ratio [HR], 2.73), and previous oral corticosteroid treatment was associated with halvin

253 An oral corticosteroid treatment was started.

254 phone survey of patients receiving long-term oral corticosteroid treatment.

255 inical outcomes including exacerbation rate, oral corticosteroid usage, forced expiratory volume in 1

256 cerbations were defined by antibiotic and/or oral corticosteroid use (moderate) or need for hospitali

257 severe in patients with a history of chronic oral corticosteroid use (P = .01), drug (P = .04) or sev

258 of CORT) was associated with the absence of oral corticosteroid use (Q = 0.04) in all cohorts and hi

259 lth care utilization (r = 0.48; P = .03) and oral corticosteroid use (r = 0.43; P = .05) at baseline.

260 umab was also associated with a reduction in oral corticosteroid use and BEC, and an improvement in l

261 e in variables including pulmonary function, oral corticosteroid use and blood tests.

262 linear models on brush samples demonstrated oral corticosteroid use as an important factor affecting

263 Moreover, adjusted oral corticosteroid use exhibited no significant change

264 Oral corticosteroid bursts (defined as oral corticosteroid use for 14 days).

265 Oral corticosteroid use prior to and following tofacitin

266 sits and/or hospitalizations and the absence oral corticosteroid use while on inhaled corticosteroid

267 ly more frequent rescue-inhaler use, greater oral corticosteroid use, and a greater rate of hospitali

268 d that worse eye visual acuity, >6 months of oral corticosteroid use, and current antidepressant use

269 exacerbations, improve lung function, reduce oral corticosteroid use, and improve quality of life in

270 efined as no exacerbations for 24 months, no oral corticosteroid use, and partly/well-controlled symp

271 ergency department visits, hospitalizations, oral corticosteroid use, and the composite outcome of th

272 uveitis control, including flare frequency, oral corticosteroid use, or nonbiologic immunomodulatory

273 oking, body mass index, diabetes, inhaled or oral corticosteroid use, study site and clinical predict

274 onal exhaled nitric oxide levels, along with oral corticosteroid use, that could predict the subtypes

275 nitric oxide levels, exacerbation rates, and oral corticosteroid use, whereas group 3 patients showed

276 sthma severity, health care utilization, and oral corticosteroid use.

277 ging immunomodulatory treatment, and current oral corticosteroid use.

278 ever, it appeared more effective in reducing oral corticosteroid use.

279 visual acuity in the worse eye and long-term oral corticosteroid use.

280 httime symptoms once a week or more, and (5) oral corticosteroid use/emergency department visits.

281 nic rhinosinusitis with nasal polyposis, low oral corticosteroids use and low body mass index represe

282 Oral corticosteroids use is frequent for asthma patients

283 Substitution with allopurinol and oral corticosteroids was also evident.

284 In both data sources, use of oral corticosteroids was associated with herpes zoster r

285 Long-term use of oral corticosteroids was defined as cumulative supply of

286 Initial treatment with topical and oral corticosteroids was ineffective.

287 chedule stratified by whether treatment with oral corticosteroids was required.

288 Carbogen inhalation and oral corticosteroids were also given.

289 Higher doses of preadmission oral corticosteroids were associated with a lower incide

290 g for prespecified confounders, preadmission oral corticosteroids were associated with a lower incide

291 Exacerbations identified by the need for oral corticosteroids were associated with more symptoms

292 Among ICU patients with sepsis, preadmission oral corticosteroids were independently associated with

293 In multivariable analyses, preadmission oral corticosteroids were not associated with in-hospita

294 Oral corticosteroids were prescribed for severe exacerba

295 The number of days on which oral corticosteroids were used was similar in the two gr

296 ional controller medication, with or without oral corticosteroids, were randomized to tezepelumab 210

297 Prevention Program recommend the addition of oral corticosteroids, which are associated with substant

298 by analysing separately four small trials of oral corticosteroids with altogether 120 participants, i

299 ulmonary disease receiving prescriptions for oral corticosteroids with cumulative prednisolone equiva

300 within the past year, atopy, and receipt of oral corticosteroids within 48 hours before arrival in t